July 31, 2024 12:54 PM EDT

FDA questions Zevra’s resubmitted data for rare disease drug ahead of adcomm

Lei Lei Wu

News Reporter

Ahead of an advisory meeting Friday, the FDA raised questions about the strength of human, mouse and cell data Zevra Therapeutics generated for its treatment …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA questions Zevra’s resubmitted data for rare disease drug ahead of adcomm

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

All of 23andMe's independent board members resign over disagreements with CEO

With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

Roivant makes another deal, selling Dermavant to Organon for up to $1.2B

Breaking down silos with a new quantitative approach to drug development

FDA ques­tions Zevra’s re­sub­mit­ted da­ta for rare dis­ease drug ahead of ad­comm

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

FDA can­cels Ap­plied Ther­a­peu­tics ad­comm, shares sky­rock­et 65%

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

With few ef­fi­ca­cy de­tails, In­sil­i­co claims a Phase 2a win in lat­est AI read­out

Roivant makes an­oth­er deal, sell­ing Der­ma­vant to Organon for up to $1.2B

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

FDA questions Zevra’s resubmitted data for rare disease drug ahead of adcomm

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

All of 23andMe's independent board members resign over disagreements with CEO

With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

Roivant makes another deal, selling Dermavant to Organon for up to $1.2B

Breaking down silos with a new quantitative approach to drug development